Mary Caffrey

A study based on a decade's worth of Korean insurance data found that use of direct oral anticoagulants (DOACs) to address atrial fibrillation and venous thromboembolism in patients with myeloproliferative neoplasms (MPNs) is effective, with acceptable bleeding risk.

The 21st annual meeting of the International Myeloma Society (IMS) takes place September 25-28, 2024, in Rio de Janeiro, Brazil.

Researchers from Bulgaria conduct an analysis of the potential for therapeutic vaccines in by comparing testing results for patients from their country with an international data set.

Based on an Avalere Health report, Community Oncology Alliance warns that IRA negotiations could slice down payments needed to administer cancer drugs.

Inflammation and genetic mutations can drive cardiovascular complications in patients with myeloproliferative neoplasms, which include disorders such as polycythemia vera, essential thrombocythemia, and primary myelofibrosis.

A review by authors from China examines evidence involving different treatment approaches.

Attendees of the first Institute for Value-Based Medicine® regional event will hear top experts from Boston-area institutions speak about treating non–small cell lung cancer, targeting HER2 in breast cancer, and identifying biomarkers in sarcomas.

The annual meeting of oncology stakeholders presented by The American Journal of Managed Care® takes place September 12-13, 2024.

Infectious diseases were the leading causes of death on the first Labor Day, just ahead of a major epidemiological shift that brought both vaccines to fight these deadly ailments but also the rise of cigarette smoking.

In this review, authors explain the supply chain issues of getting a life-saving treatment "vein to vein."

United Urology Group, with 4 practices in Maryland, Colorado, Arizona, and Tennessee, has agreed to be acquired by OneOncology, which last year was acquired by TPG and AmeriSourceBergen in a $2.1 billion transaction.

A review of the upcoming schedule of the Institute for Value-Based Medicine.

The immunotherapy combination was initially more costly but resulted in a lower cost of care over a 2-year period, investigators found.

A session on the final day of the 2024 Congress of the American Society of Preventive Cardiology explored the connections between autoimmune disease and cardiac events.

A debate on whether testing Lp(a) levels is actionable in primary prevention today offered lively discussion at the 2024 Congress of the American Society for Preventive Cardiology, being held in Salt Lake City, Utah.

A joint session with the Society for Cardiovascular Computed Tomography (SCCT) took place on the first day of the American Society for Preventive Cardiology 2024 Congress in Salt Lake City, Utah.

New Jersey Governor Phil Murphy joined BeiGene CEO John Oyler and about 300 guests to open the facility, located in Hopewell, New Jersey. A version of this article appeared in the August issue of Evidence-Based Oncology.

We recently spoke with Tycel Phillips, MD, associate professor, Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, about his team’s interim analysis of their dose-escalation study of glofitamab against relapsed/refractory B-cell non-Hodgkin lymphoma.

Matthew Zachary, the keynote speaker for Patient-Centered Oncology Care 2024, recalls what the treatment experience was like when he was diagnosed with a rare pediatric brain cancer in 1996. Zachary is now a patient advocate.